Vertex Pharmaceuticals: A Buy After FDA Approval of New Pain Drug?

Vertex Pharmaceuticals (VRTX) has received FDA approval for its new pain drug, VX-548, which is expected to significantly impact the company's revenue projections and valuation. This article explores the potential market opportunities, competition, and implications for Vertex's market share and pricing strategy following the approval of VX-548.